世界のトリプルネガティブ乳がん治療市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)

GlobalInfoResearchが発行した調査報告書(GIR20DC12231)
◆英語タイトル:Global Triple-Negative Breast Cancer Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025
◆商品コード:GIR20DC12231
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2020年12月(※2024年版があります。お問い合わせください。)
◆ページ数:102
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2~3日)
◆調査対象地域:グローバル
◆産業分野:医療、製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、トリプルネガティブ乳がん治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。トリプルネガティブ乳がん治療の種類別市場規模(アルキル化剤、植物製品、微生物製品、代謝拮抗剤、微小管安定剤)、用途別市場規模(病院薬局、小売薬局)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Celgene、Merck & Co., Inc.、Roche、Immunomedics GmbH、Eisai Co., Ltd、F. Hoffmann-La Roche Ltd、
・地域別グローバル市場分析 2015年-2020年
・トリプルネガティブ乳がん治療の北米市場(アメリカ、カナダ、メキシコ)
・トリプルネガティブ乳がん治療のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・トリプルネガティブ乳がん治療のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・トリプルネガティブ乳がん治療の南米市場(ブラジル、アルゼンチン)
・トリプルネガティブ乳がん治療の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:アルキル化剤、植物製品、微生物製品、代謝拮抗剤、微小管安定剤
・用途別分析:病院薬局、小売薬局
・地域別市場規模予測 2021年-2025年
・調査の結果・結論
【レポートの概要】

Market Overview
The global Triple-Negative Breast Cancer Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Triple-Negative Breast Cancer Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Triple-Negative Breast Cancer Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Triple-Negative Breast Cancer Treatment market has been segmented into:
Alkylating Agents
Plant Products
Microorganism Products
Antimetabolites
Microtubule Stablizing Agents

By Application, Triple-Negative Breast Cancer Treatment has been segmented into:
Hospital Pharmacies
Retail Pharmacies

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Triple-Negative Breast Cancer Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Triple-Negative Breast Cancer Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Triple-Negative Breast Cancer Treatment market.

The report offers in-depth assessment of the growth and other aspects of the Triple-Negative Breast Cancer Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Triple-Negative Breast Cancer Treatment Market Share Analysis
Triple-Negative Breast Cancer Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Triple-Negative Breast Cancer Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Triple-Negative Breast Cancer Treatment sales, revenue and market share for each player covered in this report.

The major players covered in Triple-Negative Breast Cancer Treatment are:
Celgene
Merck & Co., Inc.
Roche
Immunomedics GmbH
Eisai Co., Ltd
F. Hoffmann-La Roche Ltd

【レポートの目次】

Table of Contents

1 Triple-Negative Breast Cancer Treatment Market Overview
1.1 Product Overview and Scope of Triple-Negative Breast Cancer Treatment
1.2 Classification of Triple-Negative Breast Cancer Treatment by Type
1.2.1 Global Triple-Negative Breast Cancer Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Triple-Negative Breast Cancer Treatment Revenue Market Share by Type in 2019
1.2.3 Alkylating Agents
1.2.4 Plant Products
1.2.5 Microorganism Products
1.2.6 Antimetabolites
1.2.7 Microtubule Stablizing Agents
1.3 Global Triple-Negative Breast Cancer Treatment Market by Application
1.3.1 Overview: Global Triple-Negative Breast Cancer Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.4 Global Triple-Negative Breast Cancer Treatment Market by Regions
1.4.1 Global Triple-Negative Breast Cancer Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Triple-Negative Breast Cancer Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Triple-Negative Breast Cancer Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Triple-Negative Breast Cancer Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Triple-Negative Breast Cancer Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Triple-Negative Breast Cancer Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Triple-Negative Breast Cancer Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Celgene
2.1.1 Celgene Details
2.1.2 Celgene Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Celgene SWOT Analysis
2.1.4 Celgene Product and Services
2.1.5 Celgene Triple-Negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Merck & Co., Inc.
2.2.1 Merck & Co., Inc. Details
2.2.2 Merck & Co., Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Merck & Co., Inc. SWOT Analysis
2.2.4 Merck & Co., Inc. Product and Services
2.2.5 Merck & Co., Inc. Triple-Negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Roche SWOT Analysis
2.3.4 Roche Product and Services
2.3.5 Roche Triple-Negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Immunomedics GmbH
2.4.1 Immunomedics GmbH Details
2.4.2 Immunomedics GmbH Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Immunomedics GmbH SWOT Analysis
2.4.4 Immunomedics GmbH Product and Services
2.4.5 Immunomedics GmbH Triple-Negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Eisai Co., Ltd
2.5.1 Eisai Co., Ltd Details
2.5.2 Eisai Co., Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Eisai Co., Ltd SWOT Analysis
2.5.4 Eisai Co., Ltd Product and Services
2.5.5 Eisai Co., Ltd Triple-Negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 F. Hoffmann-La Roche Ltd
2.6.1 F. Hoffmann-La Roche Ltd Details
2.6.2 F. Hoffmann-La Roche Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 F. Hoffmann-La Roche Ltd SWOT Analysis
2.6.4 F. Hoffmann-La Roche Ltd Product and Services
2.6.5 F. Hoffmann-La Roche Ltd Triple-Negative Breast Cancer Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Triple-Negative Breast Cancer Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Triple-Negative Breast Cancer Treatment Players Market Share
3.2.2 Top 10 Triple-Negative Breast Cancer Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Triple-Negative Breast Cancer Treatment Revenue and Market Share by Regions
4.2 North America Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
5 North America Triple-Negative Breast Cancer Treatment Revenue by Countries
5.1 North America Triple-Negative Breast Cancer Treatment Revenue by Countries (2015-2020)
5.2 USA Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
6 Europe Triple-Negative Breast Cancer Treatment Revenue by Countries
6.1 Europe Triple-Negative Breast Cancer Treatment Revenue by Countries (2015-2020)
6.2 Germany Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
6.4 France Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Triple-Negative Breast Cancer Treatment Revenue by Countries
7.1 Asia-Pacific Triple-Negative Breast Cancer Treatment Revenue by Countries (2015-2020)
7.2 China Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
7.5 India Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
8 South America Triple-Negative Breast Cancer Treatment Revenue by Countries
8.1 South America Triple-Negative Breast Cancer Treatment Revenue by Countries (2015-2020)
8.2 Brazil Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Triple-Negative Breast Cancer Treatment by Countries
9.1 Middle East & Africa Triple-Negative Breast Cancer Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Triple-Negative Breast Cancer Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Triple-Negative Breast Cancer Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Triple-Negative Breast Cancer Treatment Market Forecast by Type (2019-2024)
10.3 Alkylating Agents Revenue Growth Rate (2015-2025)
10.4 Plant Products Revenue Growth Rate (2015-2025)
10.5 Microorganism Products Revenue Growth Rate (2015-2025)
10.6 Antimetabolites Revenue Growth Rate (2015-2025)
10.7 Microtubule Stablizing Agents Revenue Growth Rate (2015-2025)
11 Global Triple-Negative Breast Cancer Treatment Market Segment by Application
11.1 Global Triple-Negative Breast Cancer Treatment Revenue Market Share by Application (2015-2020)
11.2 Triple-Negative Breast Cancer Treatment Market Forecast by Application (2019-2024)
11.3 Hospital Pharmacies Revenue Growth (2015-2020)
11.4 Retail Pharmacies Revenue Growth (2015-2020)
12 Global Triple-Negative Breast Cancer Treatment Market Size Forecast (2021-2025)
12.1 Global Triple-Negative Breast Cancer Treatment Market Size Forecast (2021-2025)
12.2 Global Triple-Negative Breast Cancer Treatment Market Forecast by Regions (2021-2025)
12.3 North America Triple-Negative Breast Cancer Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Triple-Negative Breast Cancer Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Triple-Negative Breast Cancer Treatment Revenue Market Forecast (2021-2025)
12.6 South America Triple-Negative Breast Cancer Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Triple-Negative Breast Cancer Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

...

【掲載企業】

Celgene、Merck & Co., Inc.、Roche、Immunomedics GmbH、Eisai Co., Ltd、F. Hoffmann-La Roche Ltd、

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のトリプルネガティブ乳がん治療市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)(Global Triple-Negative Breast Cancer Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025)]についてメールでお問い合わせはこちらでお願いします。